High-grade neuroendocrine carcinoma of the cervix uteri

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:213777C53.0C53.1C53.8
Who is this for?
Show terms as
1Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

High-grade neuroendocrine carcinoma of the cervix uteri is an extremely rare and aggressive malignant tumor arising from neuroendocrine cells in the uterine cervix. This cancer encompasses two main histological subtypes: small cell neuroendocrine carcinoma (SCNEC) and large cell neuroendocrine carcinoma (LCNEC) of the cervix. It accounts for a very small percentage of all cervical cancers. The disease primarily affects the reproductive system but is notable for its propensity for early lymphovascular invasion and distant metastasis, commonly spreading to the lungs, liver, bone, and brain. Human papillomavirus (HPV) infection, particularly HPV types 16 and 18, has been strongly associated with the development of this tumor. Key symptoms include abnormal vaginal bleeding (postcoital, intermenstrual, or postmenopausal), vaginal discharge, and pelvic pain. In advanced stages, patients may experience symptoms related to metastatic spread, such as weight loss, fatigue, and organ-specific symptoms depending on the sites of metastasis. Some patients may also develop paraneoplastic syndromes due to ectopic hormone production by the neuroendocrine tumor cells, though this is uncommon. Due to its rarity, there are no standardized treatment protocols, but management typically involves a multimodal approach combining radical surgery, platinum-based chemotherapy (often cisplatin and etoposide, analogous to regimens used for small cell lung cancer), and radiation therapy. Despite aggressive treatment, the prognosis remains poor compared to more common cervical cancer types such as squamous cell carcinoma, with high rates of recurrence and distant metastasis. Early-stage disease may have a somewhat better outcome, but advanced-stage disease carries a significantly reduced survival rate. Clinical trials and emerging immunotherapy approaches are being explored to improve outcomes for affected patients.

Also known as:

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for High-grade neuroendocrine carcinoma of the cervix uteri.

View clinical trials →

No actively recruiting trials found for High-grade neuroendocrine carcinoma of the cervix uteri at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the High-grade neuroendocrine carcinoma of the cervix uteri community →

Specialists

1 foundView all specialists →
SP
Susan K Peterson
Specialist
PI on 1 active trial17 High-grade neuroendocrine carcinoma of the cervix uteri publications

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to High-grade neuroendocrine carcinoma of the cervix uteri.

Search all travel grants →NORD Financial Assistance ↗

Community

Open High-grade neuroendocrine carcinoma of the cervix uteriForum →

No community posts yet. Be the first to share your experience with High-grade neuroendocrine carcinoma of the cervix uteri.

Start the conversation →

Latest news about High-grade neuroendocrine carcinoma of the cervix uteri

1 articles
Clinical trialUNITERAREApr 15, 2026
New Recruiting Trial: Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas
Researchers are testing a new cancer treatment that combines two approaches: a chemotherapy drug called temozolomide and a vaccine called SurVaxM that trains th
See all news about High-grade neuroendocrine carcinoma of the cervix uteri

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about High-grade neuroendocrine carcinoma of the cervix uteri

What is High-grade neuroendocrine carcinoma of the cervix uteri?

High-grade neuroendocrine carcinoma of the cervix uteri is an extremely rare and aggressive malignant tumor arising from neuroendocrine cells in the uterine cervix. This cancer encompasses two main histological subtypes: small cell neuroendocrine carcinoma (SCNEC) and large cell neuroendocrine carcinoma (LCNEC) of the cervix. It accounts for a very small percentage of all cervical cancers. The disease primarily affects the reproductive system but is notable for its propensity for early lymphovascular invasion and distant metastasis, commonly spreading to the lungs, liver, bone, and brain. Huma

How is High-grade neuroendocrine carcinoma of the cervix uteri inherited?

High-grade neuroendocrine carcinoma of the cervix uteri follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does High-grade neuroendocrine carcinoma of the cervix uteri typically begin?

Typical onset of High-grade neuroendocrine carcinoma of the cervix uteri is adult. Age of onset can vary across affected individuals.

Which specialists treat High-grade neuroendocrine carcinoma of the cervix uteri?

1 specialists and care centers treating High-grade neuroendocrine carcinoma of the cervix uteri are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.